<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375257</url>
  </required_header>
  <id_info>
    <org_study_id>Endocarditis-DK</org_study_id>
    <nct_id>NCT01375257</nct_id>
  </id_info>
  <brief_title>Partial Oral Treatment of Endocarditis</brief_title>
  <acronym>POET</acronym>
  <official_title>Partial Oral Treatment of Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Current management of infective endocarditis include admission and treatment with
      parenteral antibiotics for 4 weeks - 6 weeks. Resource demands and psychological issues of
      present management strategy make it highly relevant to seek for alternative more lenient
      alternatives. Experiences with oral treatment are only sporadically described, but
      observational data suggest that oral treatment could be a feasible option. The investigators
      have in 2010 treated 12 endocarditis patients with partial oral antibiotics with a 100%
      success rate.

      Study design The POET study is a Danish multicenter, prospective, randomized, open label
      study. The primary aim is to show non-inferiority of partial oral treatment with antibiotics
      of endocarditis compared to full parenteral treatment. Stable patients (n=400) with
      streptococci, staphylococci or enterococci infecting the mitral valve or the aortic valve
      will be included. After a minimum of 10 days of parenteral treatment, patients will be
      randomized to oral therapy or parenteral therapy. Special recommendations for oral treatment
      have been developed based on expected minimal inhibitory concentrations and pharmacokinetic
      calculations. Patients will be followed for 6 months after completion of antibiotic therapy.
      The primary endpoint is a composition of all cause mortality, unplanned cardiac surgery,
      embolic events and relapse of positive blood cultures with the primary pathogen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is a composite endpoint including all cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen</measure>
    <time_frame>Approximately 7 months. From randomisation until 6 months after end of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Approximately 7 months. From randomisation until 6 months after end of study medication</time_frame>
    <description>QOL performed during the study and after completion of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of treatment</measure>
    <time_frame>Approximately 7 months. From randomisation until 6 months after end of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic therapy</measure>
    <time_frame>Approximately 7 months. From randomisation until 6 months after end of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications related to intravenous catheter</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Guideline treatment with parenteral antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Guideline treatment with parenteral antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral treatment with antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment with antibiotics based on resistens pattern</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral treatment with antibiotics for endocarditis</intervention_name>
    <arm_group_label>Oral treatment with antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guideline treatment with parenteral antibiotics</intervention_name>
    <arm_group_label>Guideline treatment with parenteral antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Left-sided endocarditis based on the Duke criteria

          -  Infected with one of the following microorganisms:

               -  Streptococci

               -  Enterococcus faecalis

               -  Staphylococcus aureus

               -  Coagulase-negative staphylococci.

          -  ≥ 18 years

          -  At least 10 days of appropriate parenteral antibiotic treatment overall, and at least
             1 week of appropriate parenteral treatment after valve surgery

          -  Afebrile (T &lt; 38.0) &gt; 2 days

          -  Decreasing infection parameters (CRP dropped to less than 25% of peak value or &lt; 20
             mg/l, and white blood cell count &lt; 15 x 109/l) during antibiotic treatment

          -  No sign of abscess formation by echocardiography

          -  Transthoracic and transoesophageal echocardiography performed within 48 hours prior to
             randomization

        Exclusion Criteria:

          -  Body mass index &gt; 40

          -  Concomitant infection requiring intravenous antibiotic therapy

          -  Inability to give informed consent to participation

          -  Suspicion of reduced absorption of oral treatment due to abdominal disorder

          -  Reduced compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kasper Iversen, MD</last_name>
    <phone>0045 35459863</phone>
    <email>kasper.iversen@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henning Bundgaard</last_name>
    <phone>0045 35450512</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Korup</last_name>
      <email>eva.korup@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Wiggers, MD</last_name>
      <email>henrikwiggers@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iversen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Bruun, MD</last_name>
      <email>n.eske.b@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hoslpital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Iversen</last_name>
      <email>kasper.iversen@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Tønder</last_name>
      <email>nito@0regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Sygehus</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Gill, MD</last_name>
      <email>sabine.gill@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne Elming</last_name>
      <email>hei@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Kasper Iversen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

